Cover Image
市場調查報告書

搔癢:開發平台分析

Pruritus - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213132
出版日期 內容資訊 英文 117 Pages
訂單完成後即時交付
價格
Back to Top
搔癢:開發平台分析 Pruritus - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 117 Pages
簡介

所謂搔癢是指癢造成的不舒適感,有皮膚發紅、腫、斑點、水腫、乾燥、龜裂、皮革化、鱗狀化等症狀。風險係數有溫度和過敏、氣喘、花粉症、蕁麻疹、皮膚炎等,治療方法有服用皮質類固醇劑、抗組織胺藥、抗憂鬱劑等。

本報告涵括全球搔癢治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

搔癢概要

治療藥的開發

  • 搔癢開發中產品:概要
  • 搔癢開發中產品:比較分析

搔癢:開發中的治療藥:各企業

搔癢:開發中的治療藥:大學·研究機關別

搔癢:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

搔癢:開發中的產品:各企業

搔癢:開發中的產品:大學·研究機關別

搔癢:治療藥的開發企業

  • AlbireoPharma
  • Amorepacific Corporation
  • Cara Therapeutics, Inc.
  • 中外製藥
  • Creabilis SA
  • ELORAC, Inc.
  • Faes Farma, SA
  • GlaxoSmithKline Plc
  • Hydra Biosciences, Inc.
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • NeRRe Therapeutics Ltd
  • 日本新藥
  • Patara Pharma, Inc.
  • Phosphagenics Limited
  • RDD Pharma Ltd.
  • 三和化學研究所
  • 鹽野義製藥
  • 大日本住友製藥
  • Tioga Pharmaceuticals, Inc.
  • Trevi Therapeutics, Inc.
  • Vanda Pharmaceuticals Inc.

搔癢:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • >A-4250
    • 產品概要
    • 作用機制
    • R&D的進展
  • aprepitant
  • asimadoline
  • ASN-008
  • bilastine
  • C-745
  • CR-845
  • cromolyn sodium
  • CT-327
  • CT-340
  • desloratadine
  • GSK-2330672
  • lidocaine hydrochloride
  • nalbuphine hydrochloride ER
  • naloxone hydrochloride
  • nemolizumab
  • NS-141
  • orvepitant maleate
  • PAC-14028
  • Peptides to Target TRPV1 for Pain and Itch
  • RDD-1609
  • serlopitant
  • SK-1405
  • Small Molecule to Agonize CB2 for Pruritus
  • Small Molecule to Inhibit Substance P for Pruritus
  • Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis
  • Small Molecules to Block NaV1.7 Channel for Pain and Pruritus
  • Small Molecules to Inhibit Mas-Related G-Protein Coupled Receptor for Pruritus
  • tradipitant

最新的開發平台趨勢

暫停中的計劃

中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9067IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H1 2017, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 12, 4, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pruritus - Overview
  • Pruritus - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pruritus - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pruritus - Companies Involved in Therapeutics Development
    • Albireo Pharma Inc
    • Allergan Plc
    • Alveonix AG
    • Amorepacific Corp
    • Asana BioSciences LLC
    • Cara Therapeutics Inc
    • Chugai Pharmaceutical Co Ltd
    • ELORAC Inc
    • GlaxoSmithKline Plc
    • Hydra Biosciences Inc
    • J Uriach Y Compania SA
    • NeuroCycle Therapeutics GmbH
    • Nippon Shinyaku Co Ltd
    • Patagonia Pharmaceuticals LLC
    • Patara Pharma Inc
    • Phosphagenics Ltd
    • RDD Pharma Ltd
    • Sanwa Kagaku Kenkyusho Co Ltd
    • Shionogi & Co Ltd
    • Sumitomo Dainippon Pharma Co Ltd
    • Teikoku Pharma USA Inc
    • Tioga Pharmaceuticals Inc
    • Toray Industries Inc
    • Trevi Therapeutics Inc
    • Vanda Pharmaceuticals Inc
  • Pruritus - Drug Profiles
    • A-4250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • asimadoline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ax-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ax-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cromolyn sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • difelikefalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2330672 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nalbuphine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nalfurafine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naloxone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCT-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCT-10002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCT-10004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nemolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NS-141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxinA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-14028 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PATN-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Target TRPV1 for Pain and Itch - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PR-38 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDD-1609 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rupatadine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • serlopitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SK-1405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize KOR1 for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CB2 for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TRPV3 for Pruritus, Psoriasis and Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SNA-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SNA-125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPU-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tradipitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pruritus - Dormant Projects
  • Pruritus - Discontinued Products
  • Pruritus - Product Development Milestones
    • Featured News & Press Releases
      • Jan 06, 2017: Menlo Therapeutics Starts Enrollment in Two Phase 2 Studies for Pruritus Associated with Atopic Dermatitis and Pruritus Following Burn Injury
      • Jan 05, 2017: Menlo Therapeutics Recruits Experienced Management Team and Board Leadership to Accelerate Development of Serlopitant for Treatment of Pruritus
      • Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings
      • Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting
      • Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference
      • Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain
      • Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis
      • May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845
      • Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids
      • Mar 19, 2015: Creabilis' CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board
      • Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis
      • Mar 03, 2015: Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 µg and Notice Regarding Promotion Tie-up
      • Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration
      • Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients
      • Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pruritus, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pruritus - Pipeline by Albireo Pharma Inc, H1 2017
  • Pruritus - Pipeline by Allergan Plc, H1 2017
  • Pruritus - Pipeline by Alveonix AG, H1 2017
  • Pruritus - Pipeline by Amorepacific Corp, H1 2017
  • Pruritus - Pipeline by Asana BioSciences LLC, H1 2017
  • Pruritus - Pipeline by Cara Therapeutics Inc, H1 2017
  • Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
  • Pruritus - Pipeline by ELORAC Inc, H1 2017
  • Pruritus - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Pruritus - Pipeline by Hydra Biosciences Inc, H1 2017
  • Pruritus - Pipeline by J Uriach Y Compania SA, H1 2017
  • Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H1 2017
  • Pruritus - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
  • Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H1 2017
  • Pruritus - Pipeline by Patara Pharma Inc, H1 2017
  • Pruritus - Pipeline by Phosphagenics Ltd, H1 2017
  • Pruritus - Pipeline by RDD Pharma Ltd, H1 2017
  • Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2017
  • Pruritus - Pipeline by Shionogi & Co Ltd, H1 2017
  • Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Pruritus - Pipeline by Teikoku Pharma USA Inc, H1 2017
  • Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H1 2017
  • Pruritus - Pipeline by Toray Industries Inc, H1 2017
  • Pruritus - Pipeline by Trevi Therapeutics Inc, H1 2017
  • Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H1 2017
  • Pruritus - Dormant Projects, H1 2017
  • Pruritus - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Pruritus, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top